Canada - Tiếng Anh - Health Canada

pharmascience inc - busulfan - solution - 6mg - busulfan 6mg - antineoplastic agents

Canada - Tiếng Anh - Health Canada

apotex inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents

Canada - Tiếng Anh - Health Canada

auro pharma inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents

Canada - Tiếng Anh - Health Canada

eugia pharma inc. - busulfan - solution - 60mg - busulfan 60mg

Canada - Tiếng Anh - Health Canada

marcan pharmaceuticals inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - busulfan - tablet - 2mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

aspen global inc. - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan 2 mg - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - busulfan -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - busulfan, quantity: 60 mg - injection - excipient ingredients: dimethylacetamide; macrogol 400 - busulfex is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

nexus pharmaceuticals llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. busulfan is contraindicated in patients with a history of hypersensitivity to any of its components. risk summary busulfan can cause fetal harm when administered to a pregnant woman based on animal data. busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. the solvent, dma, may also cause fetal harm when administered to a pregnant woman. in rats, dma doses of approximately 40% of the daily dose of dma in the busulfan dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies (see data ). there are no available human data informing the drug-associated risk. advise pregnant women of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk